Key Dates

Related Announcements

PAR-22-243 - Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

Issued by

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Purpose

This Notice announces the participation of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in PAR-22-243, "Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)", effective immediately.

The following sections of PAR-22-243 have been modified (changes shown inbolditalics) to reflect the participation of NICHD in this Funding Opportunity Announcement (FOA):

Part 1. Overview Information

Components of Participating Organizations

National Cancer Institute (NCI)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Neurological Disorders and Stroke (NINDS)

Assistance Listing Number(s)

93.399, 93.393, 93.394, 93.395, 93.396, 93.853, 93.865

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

IC-Specific Interest

National Institute of Child Health and Human Development (NICHD)

NICHD’s mission is to lead research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. Within the goals of this FOA, NICHD seeks innovative research to help advance this mission. Research areas of interest include, but are not limited to novel and innovative approaches and technologies to: a) improve monitoring, detection, and prevention of infectious disease and related complications in infants, children, adolescents and pregnant people, b) accelerate safe and non-invasive assessment of human placental development and function in real time across pregnancy, c) facilitate emergency and trauma care, d) improve access to function-restoring modalities in people with physical disabilities, (e) mitigate functional impairment in children with autism and intellectual and learning disabilities or developmental delays, (f) reduce pediatric healthcare- and treatment-related distress and pain, and (g) reduce disparities in gynecologic disease and maternal and pediatric health outcomes.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Toyin Ajisafe, PhD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-827-9242
Email: toyin.ajisafe@nih.gov

Financial/Grants Management Contact(s)

Margaret Young
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-642-4552
Email: margaret.young@nih.gov

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Toyin Ajisafe, PhD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-827-9242
Email: toyin.ajisafe@nih.gov